Prevalence of Antidiabetic Drugs Prescription in Type 2 Diabetes and Chronic Kidney Disease Patients from Tâmega e Sousa

Journal of diabetes and treatment Pub Date : 2022-03-28 DOI:10.29011/2574-7568.001097

Sousa, R. Abreu

{"title":"Prevalence of Antidiabetic Drugs Prescription in Type 2 Diabetes and Chronic Kidney Disease Patients from Tâmega e Sousa","authors":"Sousa, R. Abreu","doi":"10.29011/2574-7568.001097","DOIUrl":null,"url":null,"abstract":"Background: Diabetes mellitus is the most prevalent cause of Chronic Kidney Disease (CKD). Recently, guidelines have supported the use of SGLT-2 inhibitors as first-line therapy in type 2 diabetes mellitus. There is a lack of epidemiologic studies on the patterns and trends of antidiabetic drugs prescription most commonly used in clinical practice in CKD patients. Methods: A descriptive and observational single-center study was performed in 2020, by analyzing patients followed up in the Nephrology Department of the Centro Hospitalar Tâmega e Sousa, Portugal. Results: A total of 566 patients were observed over one year and 47.0% had diabetes mellitus (n=266). Mean age of diabetic patients was of 74±10.8 years, with a male gender predominance of 57.1% (n=152). Diabetic nephropathy was present in 89.5% (n=238). Remaining causes of chronic kidney disease (CKD) were hypertensive nephrosclerosis (n=12), chronic pyelonephritis (n=6), IgA nephropathy (n=2), focal segmental glomerulosclerosis (n=2), acute tubular necrosis (n=2), mesangio proliferative glomerulonephritis (n=1), immunotactoid glomerulonephritis (n=1), minimal change disease (n=1) and uncertainly (n=1). Mean HbA1c was 7.2±1.4. Mean value of plasmatic creatinine was 1.8±0.7 mg/dL (ClCr: 47±29.6 mL/min) and proteinuria was 1339±2794 mg/24h. One-third of patients were in CKD stage 3b (33.4%), 30.4% in stage 4 and 2.6% in stage 5. Oral antidiabetic drugs were prescribed an average of 1.5±0.7. DPP-4 inhibitors were the most commonly prescribed class of antidiabetic drugs (56.4%), followed by biguanides (32.7%) and SGLT-2 inhibitors (22.6%; n=60). Conclusions: A new pattern in antidiabetic drugs prescription could be seen but there is an even broader edge for treatment optimization in type 2 Diabetes Mellitus. Journal of Diabetes and Treatment Abreu R. J Diabetes Treat 7: 1097. www.doi.org/10.29011/2574-7568.001097 www.gavinpublishers.com","PeriodicalId":73707,"journal":{"name":"Journal of diabetes and treatment","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of diabetes and treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29011/2574-7568.001097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Diabetes mellitus is the most prevalent cause of Chronic Kidney Disease (CKD). Recently, guidelines have supported the use of SGLT-2 inhibitors as first-line therapy in type 2 diabetes mellitus. There is a lack of epidemiologic studies on the patterns and trends of antidiabetic drugs prescription most commonly used in clinical practice in CKD patients. Methods: A descriptive and observational single-center study was performed in 2020, by analyzing patients followed up in the Nephrology Department of the Centro Hospitalar Tâmega e Sousa, Portugal. Results: A total of 566 patients were observed over one year and 47.0% had diabetes mellitus (n=266). Mean age of diabetic patients was of 74±10.8 years, with a male gender predominance of 57.1% (n=152). Diabetic nephropathy was present in 89.5% (n=238). Remaining causes of chronic kidney disease (CKD) were hypertensive nephrosclerosis (n=12), chronic pyelonephritis (n=6), IgA nephropathy (n=2), focal segmental glomerulosclerosis (n=2), acute tubular necrosis (n=2), mesangio proliferative glomerulonephritis (n=1), immunotactoid glomerulonephritis (n=1), minimal change disease (n=1) and uncertainly (n=1). Mean HbA1c was 7.2±1.4. Mean value of plasmatic creatinine was 1.8±0.7 mg/dL (ClCr: 47±29.6 mL/min) and proteinuria was 1339±2794 mg/24h. One-third of patients were in CKD stage 3b (33.4%), 30.4% in stage 4 and 2.6% in stage 5. Oral antidiabetic drugs were prescribed an average of 1.5±0.7. DPP-4 inhibitors were the most commonly prescribed class of antidiabetic drugs (56.4%), followed by biguanides (32.7%) and SGLT-2 inhibitors (22.6%; n=60). Conclusions: A new pattern in antidiabetic drugs prescription could be seen but there is an even broader edge for treatment optimization in type 2 Diabetes Mellitus. Journal of Diabetes and Treatment Abreu R. J Diabetes Treat 7: 1097. www.doi.org/10.29011/2574-7568.001097 www.gavinpublishers.com

查看原文本刊更多论文

Tâmega e Sousa地区2型糖尿病和慢性肾脏病患者抗糖尿病药物处方的患病率

背景：糖尿病是慢性肾脏病（CKD）最常见的病因。最近，指南支持使用SGLT-2抑制剂作为2型糖尿病的一线治疗。目前缺乏对CKD患者临床实践中最常用的抗糖尿病药物处方模式和趋势的流行病学研究。方法：2020年进行了一项描述性和观察性的单中心研究，分析了葡萄牙Tâmega e Sousa中心医院肾病科的随访患者。结果：一年内共观察到566例患者，其中47.0%的患者患有糖尿病（n=266）。糖尿病患者的平均年龄为74±10.8岁，其中男性占57.1%（n=152）。糖尿病肾病发生率为89.5%（n=238）。慢性肾脏疾病（CKD）的其余病因是高血压性肾硬化症（n=12）、慢性肾盂肾炎（n=6）、IgA肾病（n=2）、局灶性节段性肾小球硬化症（n=2）、急性肾小管坏死（n=2。平均HbA1c为7.2±1.4。血浆肌酐平均值为1.8±0.7 mg/dL（ClCr:47±29.6 mL/min），蛋白尿为1339±2794 mg/24h。三分之一的患者处于CKD 3b期（33.4%），30.4%处于4期，2.6%处于5期。口服抗糖尿病药物的处方平均为1.5±0.7。DPP-4抑制剂是最常见的抗糖尿病药物（56.4%），其次是双胍类药物（32.7%）和SGLT-2抑制剂（22.6%；n=60）。结论：在2型糖尿病患者中，可以看到一种新的抗糖尿病药物处方模式，但在优化治疗方面还有更广阔的优势。糖尿病与治疗杂志Abreu R.J糖尿病治疗7：1097。www.doi.org/10.29011/2574-7568.001097 www.gavinpublishers.com

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of diabetes and treatment

自引率

0.00%

发文量